74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Regeneron Pharmaceuticals Inc
Closed
SectorHealthcare
599.49 1.95
Overview
Share price change
24h
Min
582.49
Max
600.82
Income | -423M 918M |
|---|---|
Sales | 69M 3.8B |
P/E Sector Avg | 14.641 57.333 |
EPS | 12.07 |
Dividend yield | 0.63 |
Profit margin | 24.219 |
Employees | 15,106 |
EBITDA | -534M 1.1B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +47.02% upside |
Dividend yield Sector Avg | 0.63% 2.63% |
|---|---|
Next Earnings | 29 Apr 2025 |
Market Cap | -13B 62B |
|---|---|
Previous open | 597.54 |
Previous close | 599.49 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Regeneron Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Regeneron Pharmaceuticals Inc Forecast
Price Target
By TipRanks
47.02% upside
12 Months Forecast
Average 881.75 USD 47.02%
High 1,120 USD
Low 547 USD
Based on 21 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
